Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Cunningham

Showing results (561-570 of 622) with videos related to

Pageof 63
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2022
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II TrialCatherine Thieblemont, Tycel Phillips, Herve Ghesquieres, et al.
The Journal of Pathology|December 6, 2013
The genomic landscape of oesophagogastric junctional adenocarcinomaIrene Y Chong, David Cunningham, Louise J Barber, et al.
Blood Cancer Journal|April 18, 2023
A retrospective study of MYC rearranged diffuse large B-cell lymphoma in the context of the new WHO and ICC classificationsDima El-Sharkawi, Amit Sud, Catherine Prodger, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2024
Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trialsAlessandra Raimondi, Young Woo Kim, Won Ki Kang, et al.
American Journal of Hematology|March 4, 2021
Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphomaMatthew J Maurer, Lasse H Jakobsen, Raphael Mwangi, et al.
Journal for Immunotherapy of Cancer|April 16, 2019
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoidsReyes Gonzalez-Exposito, Maria Semiannikova, Beatrice Griffiths, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2022
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP StudyJohn Bridgewater, Peter Fletcher, Daniel H Palmer, et al.
The Lancet. Haematology|April 29, 2018
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trialMary Gleeson, Clare Peckitt, Ye Mong To, et al.
Cancer Discovery|May 15, 2016
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical TrialAlex Pearson, Elizabeth Smyth, Irina S Babina, et al.
Leukemia|September 25, 2024
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trialCatherine Thieblemont, Yasmin H Karimi, Herve Ghesquieres, et al.
Pageof 63

Showing results (561-570 of 622) with videos related to

Sort By:
Pageof 63
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2022
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II TrialCatherine Thieblemont, Tycel Phillips, Herve Ghesquieres, et al.
The Journal of Pathology|December 6, 2013
The genomic landscape of oesophagogastric junctional adenocarcinomaIrene Y Chong, David Cunningham, Louise J Barber, et al.
Blood Cancer Journal|April 18, 2023
A retrospective study of MYC rearranged diffuse large B-cell lymphoma in the context of the new WHO and ICC classificationsDima El-Sharkawi, Amit Sud, Catherine Prodger, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2024
Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trialsAlessandra Raimondi, Young Woo Kim, Won Ki Kang, et al.
American Journal of Hematology|March 4, 2021
Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphomaMatthew J Maurer, Lasse H Jakobsen, Raphael Mwangi, et al.
Journal for Immunotherapy of Cancer|April 16, 2019
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoidsReyes Gonzalez-Exposito, Maria Semiannikova, Beatrice Griffiths, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2022
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP StudyJohn Bridgewater, Peter Fletcher, Daniel H Palmer, et al.
The Lancet. Haematology|April 29, 2018
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trialMary Gleeson, Clare Peckitt, Ye Mong To, et al.
Cancer Discovery|May 15, 2016
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical TrialAlex Pearson, Elizabeth Smyth, Irina S Babina, et al.
Leukemia|September 25, 2024
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trialCatherine Thieblemont, Yasmin H Karimi, Herve Ghesquieres, et al.
Pageof 63